Key facts
- This page summarizes Bruce Keyt's Form 4 filing for IGM Biosciences, Inc. (IGMS).
- 4 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 23 Jul 2024, 20:40.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Award
Award
No transaction description listed
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Disposed to Issuer
Disposed to Issuer
Additional SEC filing notes
Footnote F1
These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. One-half of the RSUs shall vest on July 19, 2025 and one-eighth of the RSUs shall vest each three-month anniversary thereafter, provided that the Reporting Person remains a service provider through each vesting date.
Footnote F2
Pursuant to the Issuer's previously disclosed option exchange program, on July 19, 2024 the Issuer cancelled the Reporting Person's options to purchase 75,000 shares and 50,000 shares of the Issuer's Common Stock and in exchange issued aggregate RSU grants of 43,888 shares and 2,778 shares.
Footnote F3
These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. One-half of the RSUs shall vest on January 19, 2026 and one-twelfth of the RSUs shall vest each three-month anniversary thereafter, provided that the Reporting Person remains a service provider through each vesting date.
Footnote F4
The shares are held directly by the Reporting Person's spouse.